IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY
Mark Monane, Robert Carlile, Kim Johnson, Darren Gitelman, Lawren VandeVrede, Leslie Jacobs, Joel Braunstein · 2024
Read IMPLEMENTATION STUDY OF THE USE OF A BLOOD BIOMARKER TEST IN ALZHEIMER’S DISEASE: CLINICIAN SURVEY FROM QUIP II STUDY by Mark Monane, Robert Carlile, Kim Johnson, Darren Gitelman, Lawren VandeVrede, Leslie Jacobs, Joel Braunstein (2024) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-11692864.txt.
Description
Mark Monane and co-authors survey the doctors who first used a blood test for Alzheimer's disease in real clinics. Blood markers promise an accurate, fair way to check patients with memory symptoms, but how the tests land in daily practice was untested. In the QUIP II study, 12 clinicians at 8 clinics used one such test with 203 patients, then rated it for usefulness and ease.
Acceptance was near the ceiling: scores averaged 9.6 out of 10, with the help in decision-making and the clarity of results rated highest. The doctors' willingness to recommend the test also scored far above the usual excellence mark. The authors say the results support building the test into routine care pathways.
Catalog record
| CREATOR | Mark Monane, Robert Carlile, Kim Johnson, Darren Gitelman, Lawren VandeVrede, Leslie Jacobs, Joel Braunstein |
|---|---|
| YEAR | 2024 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 2 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |